Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

38.36 +0.34 (+0.89%)
Official Closing Price Updated: 7:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,736,379
Open 38.25
Bid (Size) 38.13 (1)
Ask (Size) 38.15 (110)
Prev. Close 38.02
Today's Range 38.16 - 38.66
52wk Range 36.17 - 54.93
Shares Outstanding 5,606,688,356
Dividend Yield 4.07%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Shares of BioNTech Rose Friday
The company released positive trial data for a non-small cell lung cancer therapy. 
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily

Performance

YTD
-25.17%
-25.17%
1 Month
-0.23%
-0.23%
3 Month
-6.78%
-6.78%
6 Month
-24.65%
-24.65%
1 Year
-27.18%
-27.18%

More News

Read More
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
Via Investor's Business Daily
3 Undervalued Biotech Stocks to Buy Before They Blast Off
Via InvestorPlace
Why Pfizer Stock Is Perking Up Today
Via The Motley Fool
2 Ultra-Safe Dividend Stocks to Load Up On Right Now
Via The Motley Fool
Pfizer Unusual Options Activity For May 30
Via Benzinga
Pfizer Inc. (NYSE: PFE) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
7 Deeply Undervalued Growth Stocks to Buy in June
Via InvestorPlace
AI, Tech Fuel Rebound Of Vanguard Growth ETF, Eroding Value's 2022 Outperformance
Via Benzinga
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Via Investor's Business Daily
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
From Pfizer Inc.
Via Business Wire
One man’s journey with advanced prostate cancer
Via Brandpoint
Is CXApp Inc.an AI Contender or Pretender?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Have $2,000? 2 Remarkable Growth Stocks to Buy Right Now
Via The Motley Fool
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
From Pfizer Inc.
Via Business Wire
This Cannabis-Based Drug Has Outperformed Pfizer's Lyrica In Clinical Trials: A New Dawn For Diabetic Nerve Pain Management?
Via Benzinga
How Pfizer's First-Ever Approach In Hemophilia Treatment Paid Off
Via Investor's Business Daily
Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?
Via The Motley Fool
Most Active Equity Options For Midday - Wednesday, May 31
Via Talk Markets
Does Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?
Via The Motley Fool
2 Newly Minted AI Stocks to Buy Right Now
Via The Motley Fool
3 Stocks Worth Buying at 52-Week Lows
Via MarketBeat
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
From Pfizer Inc.
Via Business Wire
The 3 Best Healthcare Stocks to Buy for June 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.